Omnitrope’s Improved Delivery System Already Getting Formulary Traction
Executive Summary
Sandoz sued FDA in its effort to win approval of Omnitrope (somatropin [rDNA origin]). Now the company is using more mundane regulatory procedures as it works to expand sales of its follow-on human growth hormone
You may also be interested in...
Biosimilar But Different: Zarxio, Neupogen Diverge On Syringes, Vials
Differences in product presentation may not have much market impact now but could prove a regulatory challenge if Sandoz pursues an interchangeability determination down the line.
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry
On The Cusp Of Biosimilars: Reform Ushers In Next Generic Drug Era
The health care reform legislation signed into law by President Obama March 23 paves the way for the launch of biosimilar drugs in the U.S., action that could save the country's health care system billions of dollars, while presenting both challenges and opportunities for the drug industry